Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
1.750
+0.080 (4.79%)
At close: Apr 26, 2024, 4:00 PM
1.740
-0.010 (-0.57%)
After-hours: Apr 26, 2024, 7:06 PM EDT
Longeveron Revenue
In the year 2023, Longeveron had annual revenue of $709.00K, a decrease of -41.98%. Revenue in the quarter ending December 30, 2023 was $63.00K, a -47.93% decrease year-over-year.
Revenue (ttm)
$709.00K
Revenue Growth
-41.98%
P/S Ratio
11.84
Revenue / Employee
$30,826
Employees
23
Market Cap
8.40M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 30, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IM Cannabis | 55.11M |
| Universe Pharmaceuticals INC | 32.31M |
| Precipio | 15.20M |
| TFF Pharmaceuticals | 733.87K |
| BioRestorative Therapies | 145.80K |
LGVN News
- 2 days ago - Longeveron to Present at the Planet MicroCap Showcase - GlobeNewsWire
- 9 days ago - Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering - GlobeNewsWire
- 11 days ago - Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds - GlobeNewsWire
- 13 days ago - Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire
- 16 days ago - Longeveron Announces Closing of $5.2 Million Public Offering - GlobeNewsWire
- 19 days ago - Longeveron Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 20 days ago - Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals - GlobeNewsWire
- 5 weeks ago - Longeveron Announces 1-for-10 Reverse Stock Split - GlobeNewsWire